Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01839097
- Locations
- 🇺🇸
Hematology - Oncology Associates of Northern NJ P.A, Morristown, New Jersey, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Acrotech Biopharma Inc.
- Registration Number
- NCT01820091
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Acrotech Biopharma Inc.
- Registration Number
- NCT01789723
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01660633
- Locations
- 🇺🇸
Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Massachusetts, Worcester, Massachusetts, United States
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01583777
- Locations
- 🇪🇸
Hospital Universitario Madrid Sanchinarro, Madrid, Spain
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
- Conditions
- Interventions
- First Posted Date
- 2011-03-08
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01310244
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University Cancer Insitute, Boynton Beach, Florida, United States
🇺🇸Clearview Cancer Institute (CCI), Huntsville, Alabama, United States
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01222780
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01134341
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01118624
- Locations
- 🇫🇷
Centre Régional de Lutte Contre le Cancer Alexis Vautrin, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
🇫🇷Centre Lutte Contre le Cancer Val d'Aurelle (CRLC), Montpellier, Cedex 5, France
🇨🇿Multiscan, s.r.o., Pardubice, Czechia
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
- Conditions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 3000
- Registration Number
- NCT01110733
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States